PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 819128
Main Authors Peng, Yan, Wang, Yuanyuan, Zhou, Cheng, Mei, Wuxuan, Zeng, Changchun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.03.2022
Subjects
cancer
oncogenic alterations
Oncology
PI3K/Akt/mTOR pathway
precision medicine
targeted therapy
oncogenic alterations
targeted therapy
precision medicine
cancer
PI3K/Akt/mTOR pathway
Online AccessGet full text

Cover

More Information
Summary:Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Enrique Gonzalez Billalabeitia, Hospital Universitario 12 de Octubre, Spain; Xiaoyong Fu, Baylor College of Medicine, United States
Edited by: Yan-yan Yan, Shanxi Datong University, China
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.819128